Alimera Sciences (NASDAQ:ALIM) Research Coverage Started at Maxim Group

Maxim Group started coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note released on Monday, MarketBeat reports. The firm issued a buy rating and a $10.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com began coverage on shares of Alimera Sciences in a research note on Sunday, December 31st. They issued a hold rating on the stock.

Alimera Sciences Stock Performance

Shares of ALIM opened at $3.90 on Monday. The company’s fifty day moving average is $3.77 and its 200 day moving average is $3.56. Alimera Sciences has a fifty-two week low of $1.56 and a fifty-two week high of $4.38. The stock has a market capitalization of $204.17 million, a PE ratio of -1.81 and a beta of 1.16. The company has a debt-to-equity ratio of 1.40, a quick ratio of 2.31 and a current ratio of 2.39.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.09). Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. The business had revenue of $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. During the same quarter in the prior year, the firm posted ($0.54) EPS. Sell-side analysts expect that Alimera Sciences will post 0.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC increased its stake in Alimera Sciences by 2.3% in the 2nd quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock worth $698,000 after buying an additional 2,900 shares during the period. Vanguard Group Inc. increased its stake in Alimera Sciences by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 146,686 shares of the biopharmaceutical company’s stock worth $455,000 after buying an additional 5,293 shares during the period. Tower Research Capital LLC TRC increased its stake in Alimera Sciences by 291.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 12,000 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 8,937 shares during the period. Osaic Holdings Inc. purchased a new position in Alimera Sciences in the 2nd quarter worth about $34,000. Finally, Millennium Management LLC purchased a new position in Alimera Sciences in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.